A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma.

Saved in:
Bibliographic Details
Title: A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma.
Authors: Akkad N; Division of Cancer Medicine, Hematology/Medical Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX., Feng L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Westin JR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Hagemeister FB; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Lee HJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Fayad L; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Ahmed S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Nair R; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Rodriguez MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Strati P; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Chihara D; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Flowers CR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Claret L; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Ibanez K; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Wang M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Fowler NH; BostonGene, Waltham, MA., Henderson J; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Davis RE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Green M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Source: Blood advances [Blood Adv] 2025 Sep 09; Vol. 9 (17), pp. 4396-4404.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025016483